L. Dawson

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial

Sarah Brown, Gary Middleton, Tim Maughan et al. · The Lancet Oncology · 2013 · 392 citations · Full text

Medicine, Oncology, Pharmacology +12

Capecitabine combined with oxaliplatin (CapOx) in clinical practice: how significant is peripheral neuropathy?

D. Storey, Michelle D. Sakala, Catriona McLean et al. · Annals of Oncology · 2010 · 53 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly

L. Dawson, Duncan I. Jodrell, A. Bowman et al. · European Journal of Cancer · 2000 · 41 citations

Pharmacy, Pharmacokinetics, Pharmacology +14

Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial

Nalinie Joharatnam‐Hogan, Duaa Hatem, Fay Cafferty et al. · British Journal of Cancer · 2023 · 30 citations · Full text

Medicine, Oncology, Pharmacology +17

Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC).

Michel Seymour, Sherry-Ann Brown, Susan D. Richman et al. · Journal of Clinical Oncology · 2011 · 26 citations

Medicine, Oncology, Pharmacology +16